T2 Biosystems Reports Increased Losses and Cash Crunch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 15 2024
0mins
Source: Business Insider
Financial Performance: T2 Biosystems reported a net loss of $32.6 million for the first nine months of 2024, an improvement from a $39.7 million loss in the same period in 2023, while product revenue increased to $6 million amidst total expenses of $38.3 million.
Future Outlook: The company is facing challenges with cash reserves down to $2.6 million and may need to pursue additional financing options to sustain operations, while also addressing Nasdaq compliance issues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
